Immunogenicity of the 9-Valent Human Papillomavirus Vaccine in Occupationally-Exposed Adults.
- 1Department of Otolaryngology, Head and Neck Surgery Eastern Virginia Medical School at Old Dominion University Norfolk Virginia USA.
Abstract
HPV is the most common sexually transmitted infection and has a well-established role in the pathogenesis of recurrent respiratory papillomatosis (RRP) and oropharyngeal squamous cell carcinoma (OPSCC). HPV DNA is detectable in surgical smoke, and case reports have linked occupational exposure to laryngeal papillomatosis in healthcare workers. In 2026 a joint European Laryngological Society/Union of European Phoniatricians Delphi consensus agreed that occupational exposure is plausible and that vaccination should be offered to workers at risk, but stronger recommendations were not issued due to absence of transmission and immunogenicity data. Immunogenicity data in adults over 26-particularly men-remain minimal in the literature. In a single-center prospective study, 9-valent HPV vaccine naïve operating room staff and surgeons within otolaryngology, general surgery, urology, and obstetrics-gynecology aged 27-69 were recruited to receive the standard three-dose 9-valent vaccine. Antibody titers for HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured at baseline (Month 0) and after the completion of their vaccine series (Month 7). Of 33 enrolled adults, 21 completed the study (18 male, 3 female; mean age 36 years, range 27-61; 4 aged > 45 years). At Month 7, all 21 seroconverted for all nine types of HPV (100% seroconversion). The 9-valent HPV vaccine produced 100% seroconversion in a predominantly older, male, occupationally-exposed cohort that has been under-represented in prior research. This data suggests that offering vaccination to at-risk workers, addressing the immunogenicity gap identified by the ELS/UEP consensus. 3.
Related
- Ethical, Legal, Social, and Health System Implications of 9-valent Human Papillomavirus (9vHPV) Vaccine in the Philippines: A Scoping Review and Qualitative Study.
- Association of gut microbiota and regulatory T cells with vaccine immunogenicity in HIV-exposed uninfected and HIV-unexposed infants: a longitudinal cohort study
- 2018–2025 Serological study on avian influenza among occupationally exposed populations in the Poyang Lake area — the region with the highest environmental surveillance positive rate in China
- Cost-effectiveness of 13-valent pneumococcal vaccine for children under 5 years of age at high altitude in China : A modeling analysis
- Decision-making process and support needs regarding the human papillomavirus vaccine in Japan: a qualitative interview study with mothers
BibTeX
@article{thurber2026immunogenicity,
title = {{Immunogenicity of the 9-Valent Human Papillomavirus Vaccine in Occupationally-Exposed Adults.}},
author = {Colleen M Schinderle Thurber and Laura Stone and Craig S Derkay},
journal = {Laryngoscope investigative otolaryngology},
year = {2026},
month = nov,
doi = {10.1002/lio2.70626},
url = {https://europepmc.org/article/MED/42999688},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Immunogenicity of the 9-Valent Human Papillomavirus Vaccine in Occupationally-Exposed Adults.
AU - Colleen M Schinderle Thurber
AU - Laura Stone
AU - Craig S Derkay
PY - 2026
DA - 2026/11/06
JO - Laryngoscope investigative otolaryngology
DO - 10.1002/lio2.70626
UR - https://europepmc.org/article/MED/42999688
AB - HPV is the most common sexually transmitted infection and has a well-established role in the pathogenesis of recurrent respiratory papillomatosis (RRP) and oropharyngeal squamous cell carcinoma (OPSCC). HPV DNA is detectable in surgical smoke, and case reports have linked occupational exposure to laryngeal papillomatosis in healthcare workers. In 2026 a joint European Laryngological Society/Union of European Phoniatricians Delphi consensus agreed that occupational exposure is plausible and that vaccination should be offered to workers at risk, but stronger recommendations were not issued due to absence of transmission and immunogenicity data. Immunogenicity data in adults over 26-particularly men-remain minimal in the literature. In a single-center prospective study, 9-valent HPV vaccine naïve operating room staff and surgeons within otolaryngology, general surgery, urology, and obstetrics-gynecology aged 27-69 were recruited to receive the standard three-dose 9-valent vaccine. Antibody titers for HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured at baseline (Month 0) and after the completion of their vaccine series (Month 7). Of 33 enrolled adults, 21 completed the study (18 male, 3 female; mean age 36 years, range 27-61; 4 aged > 45 years). At Month 7, all 21 seroconverted for all nine types of HPV (100% seroconversion). The 9-valent HPV vaccine produced 100% seroconversion in a predominantly older, male, occupationally-exposed cohort that has been under-represented in prior research. This data suggests that offering vaccination to at-risk workers, addressing the immunogenicity gap identified by the ELS/UEP consensus. 3.
SN - 2378-8038
ER -